Since the discovery that treatment with oral or intravenous bisphosphonate causes bisphosphonate-related osteonecrosis of the jaws (BRONJ), numerous articles on this disease have been published. The number of causative agents was extended after intervention of RANKL-inhibitor denosumab, which has been shown to be as well associated with osteopathology of the jaws. Nonetheless, knowledge of the specific pathogenesis of this clinical entity remains lacking, and no standardized treatment protocols are available. Therefore, despite the vast literature on osteonecrosis of the jaws, there is still considerable ambiguity regarding the optimum treatment of this disease, especially among general practitioners who deal increasingly with bisphosphonates.
Jacobsen C, Zemann W, Obwegeser JA, Seifert B, Gratz KW, et al. (2012) Treatment of Osteopathology of the Jaws Associated with Bone Resorption Inhibitors: An 8-Year Single-Centre Experience. Dentistry 2:146.